Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma
- First Online:
- 185 Downloads
Anti-Human Epithelial Receptor Type 2 (HER2) antibodies have the ability to induce in vitro apoptosis of glioblastoma (GBM) cells. This study was designed to evaluate the variability of HER2 expression in GBM and its role as a possible prognosis factor.
Data of 57 patients with GBM and 16 patients with grade III gliomas were retrospectively analyzed. The expression of HER2 was determined by immunohistochemistry and intensity was noted from 0+ to 3+. We compared the HER2 expression in de novo GBM and in GBM resulting from anaplastic transformation of low-grade glioma (“secondary GBM”). Statistical analysis was performed using univariate analysis and the Kaplan–Meier method.
All GBM expressing highly HER2 (2+ and 3+) were de novo GBM. All secondary GBM expressed HER2 with low intensity (0+ and 1+). Survival time was significantly longer when HER2 expression was low (Log Rank test P = 0.04). The patterns of HER2 expression were similar between grade III gliomas and secondary GBM.
To our best knowledge, our study showed for the first time a significant association between HER2 expression and the type of GBM, with subsequent influence on survival rate. GBM with low-HER2 expression are more likely to be secondary GBM, carrying a better prognosis than de novo GBM.
KeywordsGlioblastoma De novo glioblastoma Secondary glioblastoma HER2 Survival
Blood Brain barrier
Human Epithelial Receptor Type 2
Tissue Micro array
World Health Organization
O6-methyl guanine-DNA methyl transferase
- 1.Kleihues P, Cavenee WK (eds) (2000) Tumours of the nervous central system. Pathology and genetics. World health organization of tumours. IARC Press, Lyon, pp 55–69Google Scholar
- 5.Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, Demonte F, Lang FF, McCutheon IE, Hassenbuch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extend of resection of resection and survival. J Neurosurg 95:190–198PubMedGoogle Scholar
- 8.Hegi ME, Diserens AC, Gorlia T, Hamou MF, De Tribolet N, Weller M, Kros JM, Hainfeller JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross G, Janser RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003PubMedCrossRefGoogle Scholar
- 14.Tateishi M, Teruyoshi I, Mitsudomi T, Kanedo S, Sugimachi K (2004) Prognostic value of c-erbB2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 27:1372–1375Google Scholar
- 15.Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Twaddell T, Henderson IC, Norton L (1996) Phase II study of weekly intravenous recombinant humanized anti-p185 HER2 monolclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737–744PubMedGoogle Scholar